The integrated PROTAC offering brochure lists medicinal chemistry, bioassays, solubility / permeability / stability, PK/PD, in vivo pharmacology, safety, and toxicology, supporting lead optimization through candidate selection.
Profile review: 2026-11-05 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
The integrated PROTAC offering brochure lists medicinal chemistry, bioassays, solubility / permeability / stability, PK/PD, in vivo pharmacology, safety, and toxicology, supporting lead optimization through candidate selection.
The official annual report lists formulation development services. Recent technical job descriptions disclose preclinical and clinical formulation work and protein biologic formulation screening, process development, and transfer capabilities.
The 2026 services annual report explicitly lists salt and polymorph screening and solid-state characterization.
Biologics characterization, regulated bioanalysis and clinical biomarkers
Integrated CRO/CDMO analytical services
Program / service
Target / indication
Representative stage
Evidence & scope
PROTAC chemistry, assays, DMPK, pharmacology, and safety
Program-dependent / not disclosed · Determined by the collaboration program
Platform / services
This record does not claim platform-wide human validation
Formulation development / contract manufacturing capabilities
Defined by the client project · Defined by the client project
Services / platform
Service pages do not establish human evidence for every project
Solid-state R&D capabilities
Determined by the submitted sample and research question · Not applicable; service capability
Services / platform
Not applicable; not a human clinical program
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
A Frontiers in Pharmacology review compares direct MCL-1 inhibition with approaches that reduce its abundance, including transcriptional interventions and targeted degradation. The original abstract highlights limited single-agent activity and cardiac safety concerns with inhibitors, while positioning degradation as an unvalidated clinical strategy. Biomarker-guided combinations and dynamic BH3 profiling are discussed; this review does not report a new clinical trial.
A Communications Chemistry study reports RaPiD-mAb-MS, combining plate-based preparation with direct-infusion mass spectrometry for antibody peptide mapping. The original abstract describes analysis of 96 samples in about 1.5–2 hours, routinely exceeding 95% sequence coverage, across 28 antibodies and more than 2,000 samples. The reported comparisons cover several modifications and sequence variants; broader method suitability still requires evaluation.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
The readable brochure is copyrighted 2022. Staffing and facility capacity figures should not be treated as current 2026 information; the current team and delivery capacity require confirmation.
Available capacity, site-specific qualifications, project delivery history, pricing, and technology transfer terms require confirmation with the execution entity.
Company service pages support the stated scope but do not establish clinical validation of every dosage form or client program.
Public sources confirm service availability. Sample suitability, scope of work, pricing, turnaround time, success criteria, and the quality system require direct confirmation.
This record describes service capabilities, not the clinical progress of a drug candidate or an independent validation of service success rates.
Service-provider record; no proprietary drug pipeline implied. Confirm laboratory qualification and project suitability.
